Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Anastrozole tablets - selected U.S. labeling
Product / population
Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.
Renal method
Qualitative renal guidance; no CrCl threshold for dose reduction.
Source revision
Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved
2026-09-05
Local review status
Selected dosing/renal sections read; concise local summary, not full prescribing information.
U.S. product labeling / DailyMed · Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.
Renal method: Qualitative renal guidance; no CrCl threshold for dose reduction. Source date: Label revision date not separately recorded; retrieval date is not the revision date. Retrieved: 2026-09-05
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Labeled basic dosing
Give 1 mg orally once daily, with or without food. Duration is indication-specific and should follow the oncology treatment plan.
Review bone-density loss and cholesterol effects. Estrogen-containing therapy can oppose the treatment effect; concurrent tamoxifen is not recommended.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.